More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$17.31B
EPS
2.09
P/E ratio
73.7
Price to sales
5.91
Dividend yield
0.181%
Beta
1.080399
Previous close
$150.83
Today's open
$150.83
Day's range
$149.38 - $158.96
52 week range
$81.22 - $171.74
show more
CEO
Prahlad R. Singh
Employees
11000
Headquarters
Waltham, MA
Exchange
New York Stock Exchange
Shares outstanding
111586401
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
All You Need to Know About Revvity (RVTY) Rating Upgrade to Buy
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Nov 6, 2026

Madison Mid Cap Fund Q3 2026 Portfolio Activity
The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace Holdings, Ross Stores, Revvity, and Waters Corporation. The bottom five detractors for the quarter were MKS, Floor & Decor Holdings, Carlisle Companies, Moelis and Co., and Glacier Bancorp.
Seeking Alpha • Nov 6, 2026

Revvity Q3 Earnings Call Highlights
Revvity NYSE: RVTY reported third-quarter results that exceeded its expectations, supported by stronger demand in its Life Sciences segment, continued growth in Diagnostics and expanding interest in artificial intelligence-related research tools.
MarketBeat • Nov 4, 2026

Revvity Faced Off With 'Elevated Investor Expectations' — And Won
Medical research stock Revvity surged on the back of a strong third-quarter report and heightened 2026 view.
Investors Business Daily • Nov 3, 2026

Revvity, Inc. (RVTY) Q3 2026 Earnings Call Transcript
Revvity, Inc. (RVTY) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Revvity Announces Financial Results for the Third Quarter of 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 4, 2026. The Company reported GAAP earnings per share from continuing operations of $0.56, as compared to $0.41 in the same period a year ago. Revenue for the quarter was $729 million, as compared to $699 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $95 million, as compared to $82 million for the same per.
Business Wire • Nov 3, 2026

Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.29 per share. This compares to earnings of $1.18 per share a year ago.
Zacks Investment Research • Nov 3, 2026

RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up
Revvity's Q3 2026 earnings and revenues beat estimates, fueled by Life Sciences growth and margin expansion, prompting an upward revision to its annual outlook.
Zacks Investment Research • Nov 3, 2026

Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 12, 2027 to all shareholders of record at the close of business on January 22, 2027. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fr.
Business Wire • Oct 30, 2026

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?
RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
Zacks Investment Research • Oct 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Revvity Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.